Investing in medical cannabis

Medical cannabis represents a quiet revolution in alternative healthcare. Recommended by health professionals for the treatment of chronic pain, neurological disorders and the side effects of chemotherapy, it benefits from an increasingly favorable regulatory framework in Europe.

The global market is estimated to reach 444 billion USD by 2030, with over 40 countries having already legalized its medical use. Germany, Europe’s leading market, is facing a structural shortage, offering real opportunities for GACP-certified Swiss producers, with dividends expected as early as 2027 in the 5-15% range and high potential appreciation of your shares.

This is the background to our Swiss partner, located close to the German border. It has a scalable infrastructure, an AI-integrated production system and full “Seed-to-Sale” traceability. With pre-sale contracts already signed, production capacity set to quadruple, and projected profitability of between 100 and 150% in 3 to 4 years, this investment combines innovation, societal impact and high return potential.

Accessible from as little as CHF 5,000, this investment gives you a stake in a strategic player in a fast-growing sector – with dividends expected from 2027, in the order of 5 to 15%, and a high potential appreciation of your shares.

Join this entrepreneurial and therapeutic adventure, and invest in a buoyant, responsible market.